D Durect Corp
D
Gesloten
0
Overzicht
Wijziging aandelenprijs
24u
Min
Max
Werknemers | 13 |
|---|
Aanbevelingen | Neutraal |
|---|---|
12 Maanden Prognose | +30.89% upside |
Marktkapitalisatie | 51M |
|---|---|
Vorige openingsprijs | 0 |
Vorige sluitingsprijs | 0 |
Durect Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Durect Corp Prognose
Koersdoel
By TipRanks
30.89% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 2.5 USD 30.89%
Hoogste 2.5 USD
Laagste 2.5 USD
Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Durect Corp - Dist. in de afgelopen 3 maanden.
Financieel
$
Over Durect Corp
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
